LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-0.05% downside

Nieuwssentiment

By Acuity

68%

32%

307 / 345 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 mei 2026, 08:24 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mei 2026, 21:22 UTC

Winsten

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mei 2026, 20:50 UTC

Marktinformatie

Winsten

Basic Materials Roundup: Market Talk

25 mei 2026, 16:20 UTC

Marktinformatie

Winsten

Basic Materials Roundup: Market Talk

25 mei 2026, 16:01 UTC

Marktinformatie

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mei 2026, 14:43 UTC

Marktinformatie

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mei 2026, 14:15 UTC

Marktinformatie

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mei 2026, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

25 mei 2026, 12:58 UTC

Marktinformatie

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mei 2026, 12:56 UTC

Marktinformatie

Winsten

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mei 2026, 12:48 UTC

Marktinformatie

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mei 2026, 12:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

25 mei 2026, 12:34 UTC

Marktinformatie

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mei 2026, 12:10 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Delivery Hero's Assets Look Strategic -- Market Talk

25 mei 2026, 11:00 UTC

Marktinformatie

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mei 2026, 10:19 UTC

Marktinformatie

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mei 2026, 10:05 UTC

Winsten

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mei 2026, 10:04 UTC

Winsten

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mei 2026, 10:03 UTC

Winsten

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mei 2026, 10:02 UTC

Winsten

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mei 2026, 10:01 UTC

Winsten

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mei 2026, 10:00 UTC

Winsten

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q EPS MYR0.1883

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q Rev MYR17.1B

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q Net MYR1.1B

25 mei 2026, 09:38 UTC

Marktinformatie

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mei 2026, 09:33 UTC

Marktinformatie

Global Equities Roundup: Market Talk

25 mei 2026, 09:33 UTC

Marktinformatie

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mei 2026, 08:55 UTC

Marktinformatie

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Mirati Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

307 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.